OxyFile #405

LifeTECH Scientists to Present Second Abstract at the Annual 
Meeting of The American Association of Blood Banks


TORONTO, Sept. 24 1996 /CNW/ - LifeTECH (CDN-LFTK), a 
biotechnology company with proprietary sterilization technology 
for blood and blood products, announced today that the American 
Association of Blood Banks (AABB) has accepted a second abstract 
by LifeTECH scientists for presentation at the prestigious 
International Section of the AABB's 49th Annual Meeting in 
Orlando, Florida from October 12-16, 1996.

The LifeTECH scientists will present data describing the 
inactivation of viruses in Human Immunoglobulin by LifeTECH's 
Sterizone System. The abstract is entitled (Ozone (0(3)) 
Inactivation of Virus in Human IgG Solution (Abstract no.1149). 
The authors of the abstract are LifeTECH's Lilian Lee, Walter 
Dermott and Peter Lea. This research reflects the urgent need to 
sterilize Human Immunoglobulins, which are transfused into tens of 
thousands of immune-compromised patients each year. 
Immunoglobulins that are contaminated by viruses and bacteria can 
cause serious disease or death in these patients.

Walter Dermott, President and CEO, said: "In 1994, the U.S. Food 
and Drug Administration mandated that all manufacturers of 
immunoglobulin incorporate viral inactivation into their 
manufacturing processes. The acceptance by the AABB of a second 
abstract from LifeTECH reflects the growing recognition by the 
scientific community of our achievements in virus inactivation. 
Our presentations at the AABB Annual Meeting and at the 
International Society for Free Radical Research Biennial Meeting 
in Spain in October will highlight the scientific advances that 
are moving LifeTECH rapidly toward its goal of a safe global blood 
supply."

The American Association of Blood Banks is the international 
scientific association devoted to blood banking and blood 
transfusion services. AABB members are responsible for collecting 
and transfusing most of the U.S. blood supply. The 2,400 
institutions (community and hospital blood banks and hospital 
transfusion services) and 9,200 individual members of AABB include 
physicians, scientists, medical technologists, administrators and 
blood donor recruiters located in the U.S., Canada and 39 other 
countries.

LifeTECH Corporation is a Canadian biotechnology company dedicated 
to developing and commercializing innovative technologies to 
sterilize blood and other biological fluids. LifeTECH's 
Sterizone(TM) System is designed to inactivate viruses and 
bacteria in the global blood supply, including the HIV and 
Hepatitis viruses. LifeTECH common shares (LFTK) and warrants 
(LFTK.WT) trade on the Canadian Dealing Network.


From Canada Newswire